Nothing Special   »   [go: up one dir, main page]

EA201100104A1 - Фармацевтическая композиция, содержащая статин - Google Patents

Фармацевтическая композиция, содержащая статин

Info

Publication number
EA201100104A1
EA201100104A1 EA201100104A EA201100104A EA201100104A1 EA 201100104 A1 EA201100104 A1 EA 201100104A1 EA 201100104 A EA201100104 A EA 201100104A EA 201100104 A EA201100104 A EA 201100104A EA 201100104 A1 EA201100104 A1 EA 201100104A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
composition containing
containing statin
pharmaceutically acceptable
statin
Prior art date
Application number
EA201100104A
Other languages
English (en)
Other versions
EA024554B1 (ru
Inventor
Урос Оцепек
Франц Врецер
Ребека Топорисиц
Полона Буковец
Урска Юрсиц
Original Assignee
Крка, Товарна Здравил, Д. Д., Ново Место
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08159289A external-priority patent/EP2138165A1/en
Application filed by Крка, Товарна Здравил, Д. Д., Ново Место filed Critical Крка, Товарна Здравил, Д. Д., Ново Место
Publication of EA201100104A1 publication Critical patent/EA201100104A1/ru
Publication of EA024554B1 publication Critical patent/EA024554B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к твердой фармацевтической композиции, содержащей по меньшей мере один активный агент, выбранный из группы, состоящей из статинов и их фармацевтически приемлемых солей, и по меньшей мере один фармацевтически приемлемый эксципиент с низким содержанием влаги.
EA201100104A 2008-06-27 2009-06-26 Твердая лекарственная форма, содержащая розувастатин, и способ ее получения EA024554B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08159289A EP2138165A1 (en) 2008-06-27 2008-06-27 Pharmaceutical composition comprising a statin
SI200900097 2009-04-08
PCT/EP2009/004636 WO2009156173A1 (en) 2008-06-27 2009-06-26 Pharmaceutical composition comprising a statin

Publications (2)

Publication Number Publication Date
EA201100104A1 true EA201100104A1 (ru) 2011-08-30
EA024554B1 EA024554B1 (ru) 2016-09-30

Family

ID=40957425

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100104A EA024554B1 (ru) 2008-06-27 2009-06-26 Твердая лекарственная форма, содержащая розувастатин, и способ ее получения

Country Status (9)

Country Link
EP (1) EP2309992B1 (ru)
EA (1) EA024554B1 (ru)
ES (1) ES2657416T3 (ru)
HR (1) HRP20180077T1 (ru)
HU (1) HUE035402T2 (ru)
PL (1) PL2309992T3 (ru)
PT (1) PT2309992T (ru)
SI (1) SI2309992T1 (ru)
WO (1) WO2009156173A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2387566B1 (en) 2009-01-14 2014-05-07 KRKA, tovarna zdravil, d.d., Novo mesto Process for the preparation of rosuvastatin
TR201009397A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Rosuvastatin içeren farmasötik bileşimler.
JP5809467B2 (ja) * 2011-07-12 2015-11-11 エルメッド エーザイ株式会社 ピタバスタチン含有組成物及びその製造方法
US10413543B2 (en) 2015-09-01 2019-09-17 Sun Pharma Advanced Research Company Ltd. Stable multiparticulate pharmaceutical composition of rosuvastatin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US20070191318A1 (en) 2003-10-22 2007-08-16 Yatendra Kumar Process for the preparation of amorphous rosuvastatin calcium
CZ200486A3 (cs) 2004-01-16 2005-08-17 Zentiva, A.S. Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny
WO2006035277A2 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium
CA2588216A1 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
EP1912952B1 (en) 2005-06-24 2014-10-15 LEK Pharmaceuticals d.d. Process for preparing amorphous rosuvastatin calcium free of impurities
EP1968593B1 (en) * 2005-12-20 2017-08-23 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
WO2007099561A1 (en) 2006-02-27 2007-09-07 Cadila Healthcare Limited Process for preparing rosuvastatin calcium
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
WO2008062476A2 (en) * 2006-10-31 2008-05-29 Glenmark Pharmaceutical Limited Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof

Also Published As

Publication number Publication date
EP2309992B1 (en) 2017-10-25
HRP20180077T1 (hr) 2018-02-23
PL2309992T3 (pl) 2018-05-30
ES2657416T3 (es) 2018-03-05
SI2309992T1 (en) 2018-03-30
PT2309992T (pt) 2018-01-22
HUE035402T2 (en) 2018-05-02
EA024554B1 (ru) 2016-09-30
EP2309992A1 (en) 2011-04-20
WO2009156173A1 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
EA200901319A1 (ru) Композиции для назального введения
EA201170772A1 (ru) Органические соединения
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
EA200802364A1 (ru) Композиция для ухода за кожей и ее применение
EA201390662A1 (ru) Фармацевтическая композиция, содержащая дутастерид
EA201170441A1 (ru) Терапевтические противовирусные пептиды
EA201071218A1 (ru) Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью
EA201190319A1 (ru) Твердая фармацевтическая композиция, содержащая ривароксабан
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
WO2010038237A3 (en) Compositions exhibiting delayed transit through the gastrointestinal tract
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
CL2012002716A1 (es) Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica.
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
EA201170512A1 (ru) Композиция для перорального введения
EA201270087A1 (ru) Твердые фармацевтические композиции с фиксированной дозой, содержащие ирбесартан и амлодипин, их получение и их терапевтическое применение
CY1116831T1 (el) ΧΡΗΣΗ 24-norUDCA
EA201270204A1 (ru) Таблетка
EA201100430A1 (ru) Стабильная комбинированная фармацевтическая композиция
CY1108231T1 (el) Σταθερη στερεα δοσολογικη μορφη περιλαμβανουσα δεσμοπρεσσινη
MY148393A (en) Malate salts, and polymorphs of (3s, 5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
EA201070484A1 (ru) Новые конъюгаты нейртурина для фармацевтического применения
EA201100104A1 (ru) Фармацевтическая композиция, содержащая статин
EA201290229A1 (ru) Производные спиролактама и их применение
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM